Clinical Trials

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT04394858 2026-04-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

46 enrolled

Paraganglioma, Pheochromocytoma

NCT04924075 2026-04-13

MK-6482-015

322 enrolled 3 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03206060 2026-04-01

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

130 enrolled

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06041516 2026-03-27

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Phase 1 Recruiting

70 enrolled

CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06503146 2026-03-27

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

320 enrolled

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1/2 Recruiting

66 enrolled

CNSEndocrineGenitourinary

Paraganglioma, Pheochromocytoma

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

40 enrolled

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

6 enrolled

Paraganglioma, Pheochromocytoma

NCT03946527 2026-03-02

LAMPARA

10 enrolled

Phase EARLY_PHASE1 Recruiting

Paraganglioma, Pheochromocytoma

NCT05636540 2026-02-27

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

30 enrolled

Paraganglioma, Pheochromocytoma

NCT07282587 2026-02-27

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

90 enrolled

CNSEndocrineGastrointestinalGenitourinarySarcoma

Paraganglioma

NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Phase 2 Terminated

9 enrolled 11 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

NCT04711135 2026-02-12

NETTER-P

11 enrolled 14 charts 2 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT01022515 2026-02-06

PHEO

Phase NA Completed

60 enrolled

Essential Hypertension, Hypertension, Paraganglioma, Pheochromocytoma

NCT04187404 2026-01-30

Spencer

Phase 1/2 Terminated

70 enrolled 20 charts

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic